Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000523383 | SCV000617596 | pathogenic | not provided | 2017-05-05 | criteria provided, single submitter | clinical testing | The W41X nonsense variant in the NF2 gene has been reported previously in association withneurofibromatosis type 2 (Evans et al., 1998; Bonne et al., 2016). This pathogenic variant ispredicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. Additionally, The W41X variant is not observed in large population cohorts(Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). Therefore, theW41X variant is pathogenic |
Invitae | RCV000811191 | SCV000951445 | pathogenic | Neurofibromatosis, type 2 | 2023-05-27 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 449433). This premature translational stop signal has been observed in individuals with neurofibromatosis, type 2 (PMID: 9643284, 22295085, 27704245). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Trp41*) in the NF2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in NF2 are known to be pathogenic (PMID: 9643284, 16983642). |
Genome- |
RCV000811191 | SCV002045418 | pathogenic | Neurofibromatosis, type 2 | 2021-11-07 | criteria provided, single submitter | clinical testing |